Dalbavancin as chronic antibiotic suppression therapy for left ventricular assist device driveline infection due to methicillin-resistant Staphylococcus aureus: a case report

Abstract

Left Ventricular Assist Devices (LVADs) represent an important therapeutic option in the management of advanced heart failure. We report a case of 74 years-old male with a Jarvik 2000® (Jarvik Heart, New York, USA) LVAD who presented with an infection of the LVAD driveline due to methicillin-resistant Staphylococcus aureus (MRSA) that was treated with dalbavancin as chronic antimicrobial suppression therapy without adverse events and maintaining a good quality of life for more than 37 weeks. Dalbavancin could represent a valid option for the treatment of LVAD infections because of its efficacy, pharmacokinetic/pharmacodynamic proprieties, safety and tolerability.

Keywords:

• Jarvik 2000
• left ventricular assist devices
• driveline infection
• MRSA
• dalbavancin
• chronic antimicrobial suppression therapy

Disclosure statement

All authors have no competing interests to declare.

Consent

Written informed consent was obtained from the patient.

Author contributions

CP and ST conceived the study. CP, ST, RP and DR collected data and wrote the draft, DF revised the draft and supervised the whole study. All the Authors meet the ICMJE criteria for authorship.

Additional information

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.